PMID- 35935825
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220809
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - The incidence and risk factors analysis of acute kidney injury in hospitalized 
      patients received diuretics: A single-center retrospective study.
PG  - 924173
LID - 10.3389/fphar.2022.924173 [doi]
LID - 924173
AB  - Diuretics have been one of the well-known nephrotoxic drugs which can lead to 
      acute kidney injury (AKI). However, there are few real-world studies on the 
      incidence of AKI in hospitalized patients received diuretics. In the present 
      study, a single-center retrospective study was conducted in our center. The 
      clinical data of hospitalized patients received diuretics from January 2018 to 
      December 2020 was retrospectively analyzed. Among the 18,148 hospitalized 
      patients included in the study, 2,589 patients (14.26%) were judged as incidence 
      with AKI, while only 252 patients were diagnosed with AKI in the medical record. 
      Among diuretics drugs in the study, the incidence rate of AKI with torasemide was 
      the highest with 21.62%, and hydrochlorothiazide had the lowest incidence rate 
      (6.80%). The multiple logistic regression analysis suggested that complicated 
      with hypertension, anemia, pneumonia, shock, sepsis, heart failure, neoplastic 
      diseases, combined use of proton pump inhibitors (PPI) were independent risk 
      factors for AKI related to diuretics. The logic regression models for diuretics 
      related AKI were developed based on the included data. The model for 
      diuretics-AKI achieved the area under the receiver operating characteristic 
      curves (AUC) with 0.79 on 10-fold cross validation. It is urgent to improve the 
      understanding and attention of AKI in patients received diuretics for medical 
      workers, and the assessment of risk factors before the use of diuretics should be 
      contributed to the early prevention, diagnosis and treatment of AKI, and 
      ultimately reducing morbidity and improving prognosis.
CI  - Copyright (c) 2022 Zhang, Liu, Cao, Lao, Wang, Li, Huang, Tang and Li.
FAU - Zhang, Ruiqiu
AU  - Zhang R
AD  - Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First 
      Medical University and Shandong Provincial Qianfoshan Hospital, Shandong 
      Engineering and Technology Research Center for Pediatric Drug Development, 
      Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Jinan, China.
FAU - Liu, Yanxin
AU  - Liu Y
AD  - School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, 
      Nanjing, China.
FAU - Cao, Jia
AU  - Cao J
AD  - Center for Big Data Research in Health and Medicine, The First Affiliated 
      Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan 
      Hospital, Jinan, China.
FAU - Lao, Jiahui
AU  - Lao J
AD  - Center for Big Data Research in Health and Medicine, The First Affiliated 
      Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan 
      Hospital, Jinan, China.
FAU - Wang, Baobao
AU  - Wang B
AD  - Department of Nephrology, The First Affiliated Hospital of Shandong First Medical 
      University and Shandong Provincial Qianfoshan Hospital, Jinan, China.
FAU - Li, Siwen
AU  - Li S
AD  - Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First 
      Medical University and Shandong Provincial Qianfoshan Hospital, Shandong 
      Engineering and Technology Research Center for Pediatric Drug Development, 
      Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Jinan, China.
FAU - Huang, Xin
AU  - Huang X
AD  - Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First 
      Medical University and Shandong Provincial Qianfoshan Hospital, Shandong 
      Engineering and Technology Research Center for Pediatric Drug Development, 
      Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Jinan, China.
FAU - Tang, Fang
AU  - Tang F
AD  - Center for Big Data Research in Health and Medicine, The First Affiliated 
      Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan 
      Hospital, Jinan, China.
FAU - Li, Xiao
AU  - Li X
AD  - Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First 
      Medical University and Shandong Provincial Qianfoshan Hospital, Shandong 
      Engineering and Technology Research Center for Pediatric Drug Development, 
      Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Jinan, China.
LA  - eng
PT  - Journal Article
DEP - 20220722
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9355122
OTO - NOTNLM
OT  - acute kidney injury
OT  - diuretics
OT  - logic regression model
OT  - miss diagnosis
OT  - pharmacoepidemiology
OT  - risk factors
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/08/09 06:00
MHDA- 2022/08/09 06:01
PMCR- 2022/07/22
CRDT- 2022/08/08 03:39
PHST- 2022/04/20 00:00 [received]
PHST- 2022/07/01 00:00 [accepted]
PHST- 2022/08/08 03:39 [entrez]
PHST- 2022/08/09 06:00 [pubmed]
PHST- 2022/08/09 06:01 [medline]
PHST- 2022/07/22 00:00 [pmc-release]
AID - 924173 [pii]
AID - 10.3389/fphar.2022.924173 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Jul 22;13:924173. doi: 10.3389/fphar.2022.924173. 
      eCollection 2022.